Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX24.226,50-0,95 %

Gold3.356,890,00 %

Öl (Brent)70,59+2,43 %

Dow Jones44.347,09-0,68 %

US Tech 10022.779,39-0,22 %

EUR/USD1,169250,00 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Roche Holding Aktie

Aktie

ISIN: CH0012032113 WKN: 851311 Land Flagge CH

Schweiz

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

294,00

EUR

0,00 %

0,00 EUR

Letzter Kurs 12.07.25 Lang & Schwarz

Roche Holding Aktie kaufen

Geldkurs

12.07.25

293,60

EUR

85 STK

Briefkurs

12.07.25

294,40

EUR

85 STK

BEI SMARTBROKER+ HANDELN

Hinweis
Verlängerte Handelszeiten
Ab sofort von 07:30 bis 23:00 Uhr

Baader Tragding

Neueste Nachrichten

Changes to the Roche Enlarged Corporate Executive Committee 30.06.25 · globenewswire · Roche Holding
Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A 23.06.25 · globenewswire · Roche Holding
Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma 20.06.25 · globenewswire · Roche Holding
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease 16.06.25 · globenewswire · Roche Holding
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients 15.06.25 · globenewswire · Roche Holding
Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA) 04.06.25 · globenewswire · Roche Holding
Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer 03.06.25 · globenewswire · Roche Holding
New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer 31.05.25 · globenewswire · Roche Holding
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis 30.05.25 · globenewswire · Roche Holding
CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer 23.05.25 · globenewswire · Roche Holding
Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology 23.05.25 · globenewswire · Roche Holding
New two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients 23.05.25 · globenewswire · Roche Holding

1
2
3
4
5
…
8

Meistgelesen

30 Tage
12 Monate

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy ... 160 Leser
Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed ... 148 Leser
Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in ... 140 Leser
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease 128 Leser
Changes to the Roche Enlarged Corporate Executive Committee 108 Leser

Crash-Vorsorge: 1 krisensichere Dividenden-Aktie mit 3,3 % Rendite & 38 Jahre Dividendenwachstum 15796 Leser
Roche eröffnet Pharmaforschungs- und Entwicklungszentrum in Basel, um wissenschaftliche ... 828 Leser
AI Healthcare Innovations: How They're Shaping the Future for Patients and Investors 768 Leser
Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability ... 652 Leser
Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation 636 Leser
Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak 576 Leser
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral ... 544 Leser
FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer ... 520 Leser
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses 516 Leser
Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover ... 500 Leser